Dr. Xiangsheng Xiao 肖祥胜
Chief Physician
Department of Breast Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Breast cancer radical and breast-conserving surgery, chemotherapy, endocrine therapy, early diagnosis, nipple discharge management, minimally invasive lump surgery, and postoperative reconstruction.
Dr. Xiao is a Chief Physician at Sun Yat-sen University Cancer Center. Trained at Central South University Xiangya School of Medicine, Dr. Xiao worked in general and thoracic surgery before joining the Breast Department in 2006. Research focuses on breast cancer mechanisms and stem cells, with publications in journals including PLoS ONE and Molecular Cancer Therapeutics.
Name order: in Chinese the family name comes first (Xiao Xiangsheng). Papers usually list the name as Xiangsheng Xiao or Xiao X.
Selected publications
62 papers on PubMed matched by name and affiliation; 10 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Cell Dev Biol, 2021 (senior author): A Novel Pyroptosis-Associated Long Non-coding RNA Signature Predicts Prognosis and Tumor Immune Microenvironment of Patients With Breast Cancer. PubMed 34616734
- J Pers Med, 2021 (senior author): A Systemic Inflammation Response Score for Prognostic Prediction of Breast Cancer Patients Undergoing Surgery. PubMed 34069272
- Front Pharmacol, 2020 (senior author): Corrigendum: AFAP1-AS1 Promotes Epithelial-Mesenchymal Transition and Tumorigenesis Through Wnt/β-Catenin Signaling Pathway in Triple-Negative Breast Cancer. PubMed 32765285
- Biomed Pharmacother, 2020 (senior author): Corrigendum to "Linc00152 promotes tumorigenesis by regulating DNMTs in triple-negative breast cancer" [Biomed Pharmacother. 97 (2018) 1275-1281]. PubMed 32423656
- J Cancer Res Ther, 2019 (senior author): MALAT1 and BACH1 are prognostic biomarkers for triple-negative breast cancer. PubMed 31939443
- Curr Cancer Drug Targets, 2019 (senior author): Linc01638 Promotes Tumorigenesis in HER2+ Breast Cancer. PubMed 29992881
- Front Pharmacol, 2018 (senior author): AFAP1-AS1 Promotes Epithelial-Mesenchymal Transition and Tumorigenesis Through Wnt/β-Catenin Signaling Pathway in Triple-Negative Breast Cancer. PubMed 30505272
- Curr Cancer Drug Targets, 2018 (senior author): FOXP2 Promotes Tumor Proliferation and Metastasis by Targeting GRP78 in Triple-negative Breast Cancer. PubMed 29484998
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion